Clinical trial
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous…
NCT00006091 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00006091 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment |
| Official title | Arsenic Trioxide Therapy for Interferon Alpha Refractory or Intolerant Chronic Phase Chronic Myelogenous Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Enrollment | 0 |
| Start date | Jun 19, 2000 |
| Primary completion | Jan 1, 2002 |
| Completion | Jan 1, 2002 |
| First posted | Mar 16, 2004 |
| Last update posted | Nov 14, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: